Acute and subacute effects of EV iron sucrose on endothelial functions in hemodialysis patients

Renal Failure

Volumn 34, Issue 1, 2012, Pages 1-6

  Ozkurt, Sultan ^a   Ozenc, Fatma ^b   Degirmenci, Nevbahar Akcar ^b   Temiz, Gokhan ^a   Musmul, Ahmet ^b   Sahin, Garip ^a   Yalcin, Ahmet Ugur ^a  

^a ESOGU Faculty of Medicine   (Turkey)

^b ESOGU Faculty of Medicine   (Turkey)

Author keywords

Endothelial dysfunction; Hemodialysis; Iron sucrose; Oxidative stress; Vasodilatation

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; GLYCERYL TRINITRATE; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HEMODIALYSIS PATIENT; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY TEST; MALE; PRIORITY JOURNAL; REPEATED DRUG DOSE; VASODILATATION;

ADULT; AGED; ENDOTHELIUM, VASCULAR; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84055199562     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.623492     Document Type: Article

References (26)

1. Eshbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant erythropoietin. N Engl J Med. 1987;316:73-78.
2. Agarwal R. Iron oxidative stress, and clinical outcomes. Pediatr Nephrol. 2008;23:1195-1199
3. Anonymous. National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis. 2001;37:182-238.
4. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3):51.
5. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006;1:19-23.
6. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. J Am Med Assoc. 1980;243: 1726-1731. (Pubitemid 10148807)
7. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464-470.
8. Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int. 2002;61:1830-1839. (Pubitemid 34437938)
9. Charytan C, Levin N, Al Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis. 2001;37:300-307. (Pubitemid 32116021)
10. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis. 2003;41:80-83.
11. Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost. 2004;10(4):403-406. (Pubitemid 39391304)
12. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanism of cell injury. Am J Kidney Dis. 2002;40:90-103. (Pubitemid 34701216)
13. Fernandez NG, Echeverria A, Ibarrola AS, Paramo JA, Canella IC. Randomized clinical trial on acute effects of i.v. iron sucrose during hemodialysis. Nephrology. 2010;15:178-183.
14. Sǎglam F, Cavdar C, Uysal S, Cavdar Z, Camsari T. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patient. Ren Fail. 2007;29(7):849-854. (Pubitemid 350139034)
15. Dr?ke T, Witko-Sarsat V, Massy Z, et al. ?Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-2217. (Pubitemid 35222215)
16. Rooyakers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002;32:9-16. (Pubitemid 41704982)
17. Balanos L, Juanatey CG, Testa A, Ranero R. Intravenous iron sucrose dose not impair sonografic brachial vasodilatation in peritoneal dialysis patients. Adv Perit Dial. 2008;24:90-95.
18. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol. 2002;39:257-265.
19. Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, Opacic M, Simic T. Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail. 2005;27:345-351. (Pubitemid 40770615)
20. Bolton CH, Downs LG, Victory JGG, et al. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001;16:1189-1197. (Pubitemid 32547374)
21. Ghiadoni L, Cupisti A, Huang Y, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol. 2004;17:512-519. (Pubitemid 39302878)
22. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant. 1999;14:2680-2687. (Pubitemid 32208386)
23. Cavdar C, Temiz A, Yeniceriǒglu Y, et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patient. Scand J Urol Nephrol. 2003;37:77-82. (Pubitemid 36246219)
24. Ludat K, Sommerburg O, Grune T, Siems WG, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53:530-535.
25. Mimic-Oca J, Simic T, Djukanovic LJ. Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patient. Ren Fail. 2002;24:77-87. (Pubitemid 34229601)
26. Schaller G, Scheiber-Mojdehkar B, Wolzt M. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 2005;68: 2814-2822. (Pubitemid 43251028)